
The study explored the molecular mechanisms of kaempferol, a key compound in Eucommia ulmoides Oliver (EUO), on the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Through network pharmacology, CAV-1 was identified as a target molecule influenced by kaempferol. BMSCs were treated with various concentrations of kaempferol, with 10 µM proving optimal for promoting osteogenesis. Increased alkaline phosphatase (ALP) activity, calcium deposition, and elevated expression of osteogenic markers, including Collagen I, RUNX2, and OPN, were observed post-treatment. Kaempferol also inhibited CAV-1 expression, and overexpression of CAV-1 reversed its effects, reducing osteogenic differentiation. The findings suggest that kaempferol enhances bone formation by downregulating CAV-1, indicating its therapeutic potential in bone regeneration.
Like
Save
Share